<DOC>
	<DOCNO>NCT00898261</DOCNO>
	<brief_summary>RATIONALE : Studying gene express sample tumor tissue patient cancer may help doctor identify biomarkers related cancer . PURPOSE : This laboratory study look gene expression tissue patient acute lymphoblastic leukemia enrol clinical trial ECOG-2993 .</brief_summary>
	<brief_title>Gene Expression Tissue From Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Identify gene involve specific biologic process molecular function contribute mechanism BCR/ABL tyrosine kinase induces leukemic phenotype use RNA bank patient BCR/ABL-positive acute lymphoblastic leukemia ( ALL ) enrol ECOG-2993 . - Compare pattern mRNA expression BCR/ABL fusion protein patient B-lineage ALL v patient ALL cytogenetic abnormality enrol ECOG-2993 . - Determine share differ expression pattern patient BCR/ABL-positive cytogenetically negative ALL respect achievement complete remission duration disease-free overall survival . OUTLINE : This multicenter study . Total RNA isolate stored tissue sample integrity verify reverse transcription-polymerase chain reaction ( RT-PCR ) . cDNA library create total RNA gene expression analyze via microarray analysis . Genes interest analyze flow cytometry RT-PCR . PROJECTED ACCRUAL : A total 137 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis acute lymphoblastic leukemia Tissue bank protocol ECOG2993 meeting follow criterion : Leukemic blast cell population immunophenotyped detail ( e.g. , include CD25 ) ECOG 's Immunophenotyping Reference Laboratory Flow cytometric analysis gate blast cell reveal association Bcell lineage Mononuclear cell fraction use RNA isolation contain 7599 % blast ( median 85 % ) Negative TEL/AML1 , MLL/AF4 , E2A/PBX1 qualitative reverse transcriptionpolymerase chain reaction ( RTPCR ) No FLT3 gene mutation BCR/ABLpositive sample meet follow criterion : Presence ( 9 ; 22 ) ( q34 ; q11 ) standard cytogenetics Detection either p190 BCR/ABL p210 BCR/ABL transcript qualitative RTPCR Patients genetic risk factor must meet following criterion : Only normal diploid karyotype present â‰¥ 15 metaphase standard cytogenetics PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
</DOC>